Is Flexeril a Scheduled Drug?
No, Flexeril (cyclobenzaprine) is NOT a scheduled/controlled substance in the United States. Unlike carisoprodol (Soma), which is classified as a controlled substance due to its abuse and addiction potential, cyclobenzaprine does not carry this designation 1.
Key Distinctions Among Muscle Relaxants
The evidence clearly differentiates cyclobenzaprine from other muscle relaxants with abuse potential:
Carisoprodol (Soma): Explicitly classified as a controlled substance by the FDA due to escalating abuse patterns and being one of the most commonly diverted drugs in the United States 1
Cyclobenzaprine (Flexeril): Not classified as a controlled substance, though it does have withdrawal potential with long-term use 1
Benzodiazepines (diazepam, lorazepam, etc.): Schedule IV controlled substances 2
Clinical Implications
While cyclobenzaprine is not scheduled, clinicians should be aware of important considerations:
Withdrawal symptoms can occur with long-term use, including malaise, nausea, and headache lasting 2-4 days after discontinuation, though these are not life-threatening 1. When discontinuing after prolonged use, taper over 2-3 weeks to prevent withdrawal symptoms 1.
Anticholinergic effects are significant and include hallucinations, confusion, drowsiness, constipation, urinary retention, and dry mouth 1. The drug has both peripheral and central anticholinergic activity with norepinephrine potentiation 1.
Drug interactions warrant caution, particularly concomitant use with monoamine oxidase inhibitors, which may increase the potential for serotonin syndrome 1.
Prescribing Considerations
The non-scheduled status means cyclobenzaprine prescriptions do not require the additional regulatory requirements mandated for controlled substances (such as special prescription forms, quantity limits, or DEA registration). However, this does not diminish the need for appropriate clinical judgment regarding duration of therapy and monitoring for adverse effects.